| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:12080015 | IVTH | 0.00001 M | 0.00001 M | Decreased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00002 M | 0.00002 M | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00002 M | 0.00002 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000005 M | 0.000005 M | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000005 M | 0.000005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:12397409 | IVR | 3 mg/kg | 3 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:12604174 | IVR | 200 mg/L | 200 mg/L | Increased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 200 mg/L | 200 mg/L | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:15894438 | IVR | 1 - 10 mg/L | 1 - 10 mg/L | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| PMID:16144812 | IVTH | 0.00000025 - 0.000001 M | 0.0000005 - 0.000001 M | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:17123754 | IVR | 0.01 mmol/kg | 0.01 mmol/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.01 mmol/kg | 0.01 mmol/kg | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| PMID:17719163 | IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 7.5 mg/kg/day | 7.5 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 7.5 mg/kg/day | 7.5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:18308070 | IVR | 5 mg/L | 5 mg/L | Affects testicular function | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/L | 5 mg/L | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:18571719 | IVTH | 0.000006 - 0.0001 M | 0.00003 - 0.0001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.000006 - 0.0001 M | 0.00003 - 0.0001 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000006 - 0.0001 M | 0.00003 - 0.0001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000006 - 0.0001 M | 0.00003 - 0.0001 M | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| PMID:18708132 | IVR | 0.25 mg/kg | 0.25 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | - | No significant effects observed | - | |
| PMID:20153348 | IVTH | 0.0000005 M | 0.0000005 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:20219890 | IVTH | 0.000000000001 - 0.00001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.000000000001 - 0.00001 M | 0.000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| PMID:20624455 | IVTH | 0.000001 M | 0.000001 M | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.0000005 M | - | No significant effects observed | - | |
| PMID:20652474 | IVR | 25 mg/L | 25 mg/L | Increased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations |
| IVR | 25 mg/L | 25 mg/L | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/L | 25 mg/L | Increase in Growth Hormone (GH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Increased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations | |
| PMID:21287658 | IVR | 10 mg/L | 10 mg/L | Uterine hyperplasia | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/L | 10 mg/L | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| PMID:21605642 | IVR | 0.5 mg/kg | 0.5 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:23792431 | IVR | 0.6 mg/kg/day | 0.6 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.6 mg/kg/day | 0.6 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1.25 mg/kg/day | 1.25 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1.25 mg/kg/day | 1.25 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg/day | 0.3 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg/day | 0.3 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| PMID:23858299 | IVR | 0.15 mg/kg | 0.15 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.15 mg/kg | 0.15 mg/kg | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 0.15 mg/kg | 0.15 mg/kg | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.15 mg/kg | 0.15 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.15 mg/kg | 0.15 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.15 mg/kg | 0.15 mg/kg | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.15 mg/kg | 0.15 mg/kg | Induce apoptosis in mammary gland cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.075 mg/kg | 0.075 mg/kg | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 0.075 mg/kg | 0.075 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.075 mg/kg | 0.075 mg/kg | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.075 mg/kg | 0.075 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| PMID:25484011 | IVR | 5 mg/kg | 5 mg/kg | Decreased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Decreased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | - | No significant effects observed | - | |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Decreased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Decreased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Decreased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Changes in haemocrit values | Immunological endocrine-mediated pertu | |
| PMID:25744307 | IVTH | 0.000000001 - 0.0001 M | 0.00000000000001 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| PMID:25912632 | IVR | 1.5 mg/kg | 1.5 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:26668641 | IVR | 22.2 mg/kg | 22.2 mg/kg | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 22.2 mg/kg | 22.2 mg/kg | Increase in the number of abnormal sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 22.2 mg/kg | 22.2 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 22.2 mg/kg | 22.2 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| PMID:27469444 | IVR | 10 mg/L | 10 mg/L | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/L | 10 mg/L | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| PMID:28554186 | IVR | 3 mg/kg/day | 3 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| PMID:29197250 | IVR | 0.25 mg/kg | 0.25 mg/kg | Affects testicular function | Reproductive endocrine-mediated perturbations |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Alterations in number of leydig cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Alterations in number of leydig cells | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:4082073 | IVR | 5 - 6 mg/kg | 5 - 6 mg/kg | Abnormal development of gonads in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 5 - 6 mg/kg | 5 - 6 mg/kg | Affects germ cell differentiation | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:8207012 | IVTH | 0.000001 M | 0.000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Affects expression of estrogen receptor (ER) | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| PMID:8989890 | IVR | 3 mg/kg | 3 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVR | 3 mg/kg | 3 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.